The fastest growing
Neurotoxin in the last 4 years

It’s pronounced

An intentionally designed, high quality product
that drives patient satisfaction.

This page is meant for Healthcare Professionals

If you are a potential patient, please learn more about the product here.

Intentional Design

Jeuveau is a 900 kDa neurotoxin designed with purpose in California. Our unique manufacturing combines vacuum-dried processing with proprietary

Hi-Pure™ technology

resulting in ≥95% product purity and a
diffusion profile that supports results as you intend them.2,9

Unique manufacturing

900 KDA MOLECULE

Jeuveau utilizes the entire 900kDa complex. Accessory proteins are active and may contribute to the efficacy.8

HI-PURE TECHNOLOGY

Our HI-PURE™ Technology allows the purification of the toxin with at least

95% purity.1

VACUUM VS.

FREEZE-DRIED

Vacuum-dried avoids crystal formation and minimizes product impurities, maintaining the integrity of the toxin.8

THE POWER OF PRECISION IS IN YOUR HANDS

Mechanism of Action

When used in conjunction with intramuscular injection for moderate to severe glabellar lines,1,4 Jeuveau offers:

  • A precise, tight field of effect that puts control in your hands1
  • Natural-looking results, exactly where you want them4,9
  • Consistent outcomes, for consistently satisfied patients 4,9*

*87% of injectors consider Jeuveau to be a precise product when injected intramuscularly.8

Ready to try Jeuveau at your practice?

Create a Myevolus account

Results that speak volumes

Jeuveau demonstrated a proven safety profile in 5 clinical studies, all part of the Transparency Clinical Program:

  • 2 phase III pivotal studies (n=645)4
  • The largest head-to-head aesthetic EU/Canada phase III trial vs BOTOX® Cosmetic (n=540)5,* 
  • 2 long-term safety studies (n=922)6,7

In the 2 U.S. pivotal phase III studies, 68% and 70% of Jeuveau patients with moderate to severe frown lines had a 2-grade or better physician- and patient-rated improvement (none or mild frown lines) at Day 30, compared to 1% for placebo.

* Jeuveau demonstrated non-inferiority to BOTOX® Cosmetic in the treatment of moderate to severe glabellar lines in adults based on a GLS score of 0 or 1 at maximum front on Day 30 by investigator assessment.

Face Off Against

Botox® Cosmetic

At Day 30
BOTOX® Cosmetic
82.8%
of people studied
saw improvement
(n=244)
Two Jeuveau vials
At Day 30
Jeuveau
87.2%
of people studied
saw improvement
(n=235)

We’re so confident in our results, we put Jeuveau to the test against the legacy neurotoxin brand, BOTOX® Cosmetic.5

Evolus conducted the largest head-to-head aesthetic phase III study and found that Jeuveau demonstrated non-inferiority to BOTOX® Cosmetic in the treatment of moderate to severe glabellar lines in adults based on a GLS score of 0 or 1 at maximum frown on Day 30 by investigator assessment.** 

**A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment. 

Primary Endpoint

GLS score of 0 or 1 at maximum frown on day 30 by investigator assessment.

Non-inferiority margin5*: 10%

In that same study,

Jeuveau was numerically favored
in 26/30 exploratory endpoints.5*

*Investigator and subject assessment of GLS ≥1-point improvement at maximum frown at days 2, 14, 30, 90, 120, and 150.

Learn more

PATIENT SATISFACTION 

FAST ACTING LONG LASTING RESULTS 

94.5% of Jeuveau patients report being satisfied with their results, enjoying smoother frown lines in as little as two days* that last for up to four months.5†

*About 50% of people begin showing improvement after two days (≥1-grade improvement by physician assessment). Most people (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments).
†On average, Jeuveau patients receive 3 treatments a year.

Day 0 & Day 30
Day 2
Day 30
Day 120
Day 0 & Day 30
Day 2
Day 30
Day 120
Soo Youn
Soo Youn
Soo Youn
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
David
David
David
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
David
David
David
David
David
David
David
Arielle
Arielle
Arielle
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
Sarah
Sarah
Sarah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
Tajah
Tajah
Tajah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
Lisa
Lisa
Lisa
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
Tia
Tia
Tia
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tia
Tia
Tia
Tia
Tia
Tia
Tia
Shai
Shai
Shai
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Shai
Shai
Shai
Shai
Shai
Shai
Shai
Tugba
Tugba
Tugba
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
Josephine
Josephine
Josephine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
Right arrow
At maximum frown. Actual patient. Results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Soo Youn
Soo Youn
David
David
Arielle
Arielle
Sarah
Sarah
Tajah
Tajah
Lisa
Lisa
Tia
Tia
Shai
Shai
Tugba
Tugba
Josephine
Josephine
See More Results
Right arrow
At maximum frown. Jeuveau® patient. Individual results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Ready to join the Evolus Experience?

Start setting up your MyEvolus account and see all that Evolus can offer you today.

Create a Myevolus account

References

  1. Jeuveau® [package insert]. Evolus, Inc; 2023. 
  2. Kim CS, Song KY, Min KM, An YD, inventors; Daewoong Co, Ltd, assignee. Method for production of botulinum toxin. US patent 9,512,418 B2. December 6, 2016. 
  3. Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15. 
  4. Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase 3 studies. Dermatol Surg. 2019;45(11):1381-1393. 
  5. Rzany BJ, Ascher B, Avelar RL, et al. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020;40(4):413-429. 
  6. Kaufman-Janette J, Avelar RL, Biesman BS, et al. The first of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients[published correction appears in Aesthet Sur J. 2021 Nov 12;41(12):1494. doi: 10.1093/asj/sjab229]. Aesthet Surg J. 2021;41(12):1409-1422. 
  7. Lorenc ZP, Adelglass JM, Avelar RL, et al. The second of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients [published correction appears in Aesthet Surg J. 2021 Nov 12;41(12):1494-1495. doi: 10.1093/asj/sjab230]. Aesthet Surg J. 2021;41(12):1423-1438. 
  8. Avelar, Rui MD. Botulinum Toxin Accessory Proteins: Are They Just an Accessory?. Dermatologic Surgery 50(9S):p S38-S41, September 2024.
  9. Data on file; REF-00258. Evolus, Inc., Newport Beach, CA.

Discover

Jeuveau
(prabotulinumtoxinA-xvfs)
Evolysse™Evolus Rewards™Club Evolus™Beauty BlogClinical Studies

Company

CareersEvolus Investor RelationsContact Us
Terms & ConditionsPrivacy Policy

Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660

©2025 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners.

*Your Club Evolus membership covers 20 units of Jeuveau per treatment, with a minimum of 90 days between each treatment. Units do not accrue if you wait more than 90 days between treatments. You will pay your provider directly for any additional treatments you receive. Cannot be combined with any other offer. Club Evolus members will be automatically opted out of Evolus Rewards™ upon enrollment. You can manage your Club Evolus account and payment method through your club.evolus.com login. If you cancel within the first three months a $100 cancellation fee will apply. Your Club Evolus membership is non-transferable and payments are non-refundable.

IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (prabotulinumtoxinA-xvfs)

Expand
Add icon

WARNING: DISTANT SPREAD OF TOXIN EFFECT: The effects of all botulinum toxin products,including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection.Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellarlines.

CONTRAINDICATIONS

JEUVEAU is contraindicated in individuals with known hypersensitivity to any botulinum toxinpreparation or to any of the components in the formulation, and in the presence of infection at the
proposed injection site(s).